Overview
ANIX market data
Price History
ANIX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.32 – $5.46 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $127.6 · P/B 8.97 · P/S 607.57.
Company news
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine TechnologyBenzinga · Jul 14, 2026, 12:35 PM
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian CancerBenzinga · Jul 6, 2026, 12:40 PM
Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine TechnologyBenzinga · Jun 29, 2026, 12:50 PM
Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of ParticipantsBenzinga · Jun 26, 2026, 1:20 PM
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) EstimateBenzinga · Jun 10, 2026, 9:35 PM
Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine TechnologyBenzinga · Jun 1, 2026, 1:10 PM
Anixa Biosciences Announces Its Data From Phase 1 Clinical Study Of Liraltagene Autoleucel Demonstrates No Dose-Limiting Toxicities To Treat Recurrent Ovarian CancerBenzinga · May 11, 2026, 1:02 PM